Pharmaceutical preparation containing glapiramide hydrochloride and preparation method thereof
Through the preparation method of amorphous grapiline hydrochloride, the electrostatic and production problems of A crystalline grapiline after micronization treatment are solved, chemical stability and bioequivalence are achieved, production process is simplified and improved The safety of the product.
Patent Information
- Application Number
- CN202310631843.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
After micronization, A crystal grapiline has static and dust problems, which leads to inconvenient production and requires high equipment conditions. It is light in quality, poor fluidity, poor compressibility and poor hydrophilicity, affecting industrial production.
The preparation method of grapiline hydrochloride in amorphous form was adopted by 2-(4-(2-ethyl-4,6-dimethyl-1H-imidazole[4,5-c]pyridin-1-yl) Phenyl)ethylamine reacts with p-toluenesulfonyl isocyanate, combines hydrochloric acid dissolution and precipitation at low temperature to obtain stable grapiline hydrochloride, which is used to prepare pharmaceutical preparations.
Overcome the shortcomings of A crystal grapiline's poor compressibility, poor fluidity, poor water solubility and great electrostatic effects, realize the stability and bioequivalence of chemical properties, simplify the production process, reduce the requirements of production equipment, and Improves product safety.
Smart Images

Figure CN119060046A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of veterinary drugs, and specifically provides a pharmaceutical preparation containing glapiron hydrochloride and a preparation method thereof. Background Art
[0002] Prostaglandin E2 (PGE2) is one of the most common and important prostaglandins, and it plays an important role in inflammation and pain. In terms of inflammation, PGE2 causes inflammatory reactions such as tissue redness, swelling, heat and pain by promoting the infiltration and activation of leukocytes, inducing the release of inflammatory mediators, and increasing vascular permeability. PGE2 can also stimulate the proliferation and differentiation of inflammatory cells, thereby further aggravating the inflammatory response; in terms of pain, PGE2 can affect pain perception and transmission through various pathways, including promoting neuronal excitation, increasing pain sensitivity, and lowering the pain threshold. PGE2 can also mediate the release of pain-related neurotransmitters and strengthen the transmission between neurons, thereby aggravating the pain.
[0003] Grapiprant is a prostaglandin E2 subtype 4 (EP4) receptor antagonist approved by the US FDA in 2016 for the treatment of pain caused by canine arthritis. Grapiprant tablets, developed by Aletana Therapeutics Inc., are marketed under the trade name The molecular structure of glapiron is as follows:
[0004]
[0005] Patent applications CN113087705A and CN112370450A of Aletana Therapeutics, Inc., USA disclose crystalline forms of grapiron and applications of grapiron compositions. Patent CN113087705A states that the crystalline form of grapiron is crystal form A, and patent CN112370450A states that the application field of the composition is to treat pain and inflammation in non-human animals. Patent application CN113301896A of Ares Medical, Inc., USA discloses an EP4 inhibitor (grapiron) and a method for synthesizing it, and provides a grapiron composition and its application for treating proliferative disorders. Patent US20210315909A1 of Ares Medical, Inc., USA discloses crystals and salts of EP4 inhibitors (grapiron) for treating proliferative diseases, and the statement explicitly requires that its hydrochloride form is a crystal that does not contain an amorphous compound.
[0006] In general, the functional auxiliary materials that need to be added to the tablet prescription include adhesives, fillers, lubricants, disintegrants, etc. Sometimes, according to other requirements of the tablet, additional glidants, surfactants, colorants, food attractants and taste masking agents are added to improve the fluidity of the tablet intermediate and improve the solubility, color and smell of the tablet. The patent CN112370450A of Aletana Therapeutics Co., Ltd. in the United States discloses that the prescription composition of grapipiron tablets consists of fillers, adhesives, diluents, disintegrants, glidants, lubricants, flavoring agents, and surfactants. Specifically, the prescription composition in the embodiment is as follows: grapipiron (active ingredient), microcrystalline cellulose (filler), lactose (diluent), copovidone (binder), sodium carboxymethyl starch (disintegrant), sodium lauryl sulfate (surfactant), colloidal silicon dioxide (glidant), pig liver powder (flavoring agent), magnesium stearate (lubricant).
[0007] The information in patents CN113087705A and CN112370450A shows that the active and stable crystalline form of grapipiron is crystalline form A. In the process of patent reproduction, it was found that crystalline form A of grapipiron needs to be micronized, and the particle size range meets D90≤50μm and needs to be used in conjunction with surfactants to ensure that the dissolution and bioequivalence of the prepared tablets are consistent with commercially available products. In addition, on the one hand, after micronization, crystalline form A of grapipiron will generate static electricity and a large amount of dust, which is not conducive to production and labor protection, and also seriously reduces the yield of grapipiron; on the other hand, it is necessary to add glidants and adhesives to ensure the industrial production of the preparation. The discovery of the above problems shows that crystalline form A of grapipiron has the disadvantages of light weight, poor fluidity, poor compressibility, poor hydrophilicity and large electrostatic effect, and also reflects that the use of crystalline form A of grapipiron for industrial production requires a higher level of equipment conditions and technical requirements.
[0008] Drug salt formation is one of the effective means to improve the physicochemical properties of drug molecules and enhance drugability. It can change the solubility of drugs, improve their compliance, enhance their stability, and reduce adverse reactions. Studies have found that grapipiron hydrochloride can overcome the shortcomings of grapipiron in the A crystal form, such as light weight, poor compressibility, poor fluidity, poor hydrophilicity, and strong electrostatic effects, and has the same bioequivalence and quality stability as grapipiron. Therefore, it is of great significance to prepare grapipiron hydrochloride that is bioequivalent, stable and reliable to grapipiron, and it is also a challenge to break through foreign patent protection and achieve product substitution for imports.
[0009] In view of this, the present invention is proposed. Summary of the invention
[0010] The first object of the present invention is to provide a method for preparing amorphous glapiron hydrochloride.
[0011] The second object of the present invention is to provide the above-mentioned amorphous glapiron hydrochloride.
[0012] The third object of the present invention is to provide the use of the amorphous glapiron hydrochloride.
[0013] The fourth object of the present invention is to provide a pharmaceutical preparation of glapiron hydrochloride.
[0014] The fifth object of the present invention is to provide a method for preparing the above-mentioned glapiron hydrochloride pharmaceutical preparation.
[0015] In order to achieve the above object, the present invention particularly adopts the following technical solutions:
[0016] A method for preparing amorphous glapiron hydrochloride, the method comprising:
[0017] (1) 2-(4-(2-ethyl-4,6-dimethyl-1H-imidazole[4,5-c]pyridin-1-yl)phenyl)ethylamine reacts with p-toluenesulfonyl isocyanate in an organic solvent. After the reaction is completed, water is added to the resulting solution for separation. The organic phase is then dried to remove water, filtered, and the solvent is evaporated under reduced pressure to obtain a crude glabiron gel product.
[0018] (2) dissolving the crude colloidal product of grapipiron with hydrochloric acid, precipitating the solid at low temperature, and drying to obtain grapipiron hydrochloride.
[0019] The reaction equation is as follows:
[0020] Further, in step (1): a solution of p-toluenesulfonyl isocyanate dissolved in an organic solvent is added dropwise to a solution of 2-(4-(2-ethyl-4,6-dimethyl-1H-imidazole[4,5-c]pyridin-1-yl)phenyl)ethylamine, an organic solvent and triethylamine to react.
[0021] Preferably, the organic solvent used in step (1) is dichloromethane or ethyl acetate.
[0022] Furthermore, the concentration of hydrochloric acid in step (2) is 0.8 to 1.3 mol / L.
[0023] Preferably, the low temperature in step (2) is 2-8°C.
[0024] Preferably, the drying temperature in step (2) is 50-60° C., and the drying time is 6-10 h.
[0025] The preparation method prepares glapiron hydrochloride.
[0026] Use of glapiron hydrochloride in a pharmaceutical preparation. Preferably, the pharmaceutical preparation is a tablet.
[0027] A glapiron hydrochloride pharmaceutical preparation comprises 1.0% to 10.0% of a disintegrant, 10.0% to 20.0% of an appetite attractant, 0.5% to 1.5% of a lubricant and 5.0% to 10.0% of the glapiron hydrochloride of the present invention, and the balance is a filler.
[0028] Furthermore, the glapiron hydrochloride pharmaceutical preparation includes 3.0% of a disintegrant, 15.0% of an appetite attractant, 1.0% of a lubricant, 10.0% of glapiron hydrochloride and 71.0% of a filler.
[0029] Furthermore, the glapiron hydrochloride pharmaceutical preparation includes 3.0% of a disintegrant, 15.0% of an appetite attractant, 1.0% of a lubricant, 8.6% of glapiron hydrochloride and 72.4% of a filler.
[0030] Furthermore, the disintegrant is selected from at least one of sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, starch, and low-substituted hydroxypropyl cellulose, preferably cross-linked polyvinylpyrrolidone.
[0031] Preferably, the filler is selected from at least one of pregelatinized starch, microcrystalline cellulose, lactose or mannitol, preferably lactose. The type of lactose is direct compression lactose.
[0032] Preferably, the attractant is selected from one of pig liver powder, fish meal, chicken liver powder, milk powder, beef powder, meat and bone meal or yeast extract, preferably chicken liver powder.
[0033] Preferably, the lubricant is selected from one of magnesium stearate, PEG3350, PEG4000, PEG6000, sodium benzoate, and sodium stearyl fumarate, preferably magnesium stearate.
[0034] The preparation method of the drug preparation comprises the following steps: premixing the sieved glapiron hydrochloride with a disintegrant, a filler and an attractant according to a proportion, then adding a lubricant and mixing until uniform, and finally tabletting to obtain the drug preparation.
[0035] Compared with the prior art, the technical effects of the present invention are:
[0036] The amorphous glapiron hydrochloride prepared by the present invention has stable chemical properties, has low related substances (impurities) in influencing factor tests and accelerated tests, has no obvious hygroscopicity, and has no crystal form change.
[0037] The present invention finds that the amorphous glapiron hydrochloride overcomes the shortcomings of the A-crystalline glapiron, such as poor compressibility, poor fluidity, poor water solubility and large electrostatic effect, during the preparation process, and can omit the use of adhesives, glidants and surfactants, thereby simplifying the production process and reducing the requirements for production equipment. At the same time, since the product removes adhesives, surfactants and glidants, the types of auxiliary materials are reduced, and the safety of the product is relatively higher. The successful application of the invention provides a new medication option for treating pain or inflammation and proliferative diseases in dogs and cats.
[0038] The opening of the synthetic process route of grapipiron hydrochloride of the present invention makes it possible to industrially produce amorphous grapipiron hydrochloride; the application of grapipiron hydrochloride in pharmaceutical preparations proves that amorphous grapipiron hydrochloride also has similar clinical application value and commercial development value as grapipiron. BRIEF DESCRIPTION OF THE DRAWINGS
[0039] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0040] Figure 1 is the XRPD pattern of glapiron hydrochloride in Example 2;
[0041] Figure 2 is the XRPD pattern of Form A glapiron in Example 2;
[0042] Figure 3 is the UPLC-MS / MS determination result of the bioavailability of glapiron hydrochloride tablets and glapiron tablets in Example 7;
[0043] Figure 4 is a dissolution curve of glapiron hydrochloride tablets and glapiron tablets in a pH 1.2 medium in Example 6;
[0044] Figure 5 is a dissolution curve of glapiron hydrochloride tablets and glapiron tablets in pH 4.0 medium in Example 6;
[0045] Figure 6 is a dissolution curve of glapiron hydrochloride tablets and glapiron tablets in a pH 6.8 medium in Example 6;
[0046] Figure 7 is a dissolution curve of glapiron hydrochloride tablets and glapiron tablets in purified water medium in Example 6;
[0047] Figure 8 It is a dissolution curve diagram of glapiron hydrochloride tablets and glapiron tablets in purified water medium in Examples 5, 8, 9 and 10. DETAILED DESCRIPTION
[0048] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0049] The preparation route and steps of the amorphous glapiron hydrochloride of the present invention are as follows:
[0050]
[0051] Step 1: Stir an organic solvent, 2-(4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl)ethanamine and triethylamine (TEA) until completely dissolved.
[0052] Step 2: Dissolve p-toluenesulfonyl isocyanate in an organic solvent.
[0053] Step 3: Use a constant pressure dropping funnel to dropwise add the solution from step 2 to the solution from step 1, stirring while dropping. Complete the dropping within the specified time and allow to fully react at room temperature.
[0054] Step 4: After the reaction is completed, water is added to separate the phases, the organic phase is dried with anhydrous sodium sulfate, and then the solvent is removed by filtration under reduced pressure to obtain a colloidal crude product.
[0055] Step 5: Dissolve the colloidal crude product with dilute hydrochloric acid, then precipitate the solid in an ice-water bath, and dry the solid to obtain amorphous glapiron hydrochloride.
[0056] More specifically, the usage ratio of 2-(4-(2-ethyl-4,6-dimethyl-1H-imidazole [4,5-c] pyridin-1-yl) phenyl) ethylamine and triethylamine can be about 2:1; the usage ratio of 2-(4-(2-ethyl-4,6-dimethyl-1H-imidazole [4,5-c] pyridin-1-yl) phenyl) ethylamine and triethylamine can be about 1:1.5; and the concentration of dilute hydrochloric acid is about 1 mol / L.
[0057] The amorphous glapiron hydrochloride prepared by the invention has the same bioequivalence and quality stability as glapiron, and simplifies the production process in the application of preparing pharmaceutical preparations.
[0058] The glapiron hydrochloride pharmaceutical preparation provided by the present invention can be a glapiron hydrochloride tablet, which is composed of glapiron hydrochloride, a disintegrant, a filler, an appetite attractant and a lubricant, wherein the weight percentage of each component is as follows: 1.0% to 10.0% of the disintegrant, 10.0% to 20.0% of the appetite attractant, 0.5% to 1.5% of the lubricant and 5.0% to 10.0% of the glapiron hydrochloride of the present invention, and the balance is the filler.
[0059] The preparation of the glapiron hydrochloride drug comprises premixing the sieved raw material with the disintegrant, the filler and the phagostimulant, then adding a lubricant to mix them evenly, and finally tableting, subpackaging and packaging. Preferably, the glapiron hydrochloride, the disintegrant, the filler and the phagostimulant are sieved through a 40-mesh sieve, mixed evenly, and tableted by adding a lubricant.
[0060] This process overcomes the shortcomings of traditional grapipiron in the formulation process, such as poor compressibility, poor fluidity, poor water solubility and strong electrostatic effect, simplifies the formulation process and reduces industrial production conditions.
[0061] The present invention is further described below by way of examples. Unless otherwise specified, the materials in the examples are prepared according to existing methods or directly purchased from the market.
[0062] Example 1
[0063] Add 2L of dichloromethane, 200g of 2-(4-(2-ethyl-4,6-dimethyl-1H-imidazole[4,5-c]pyridin-1-yl)phenyl)ethylamine, and 100g of triethylamine to a 5L three-necked flask and stir for 10 minutes until the solid is completely dissolved. Dissolve 150g of p-toluenesulfonyl isocyanate in 0.8L of dichloromethane and add dropwise to the reaction using a constant pressure dropping funnel. Add dropwise for 1.0h and react at room temperature for 1h.
[0064] After the reaction, 2L of water was added to the reaction solution and stirred for 30min to separate the liquids. The dichloromethane phase was dried over anhydrous sodium sulfate, and the mother liquor was filtered and the solvent was evaporated to obtain a brown colloid crude product. 2.8L of 1mol / L dilute hydrochloric acid was added to the brown colloid crude product and stirred to dissolve the colloid. The mixture was cooled to 5°C in an ice-water bath and stirred for 2h to precipitate a solid. The solid was filtered and dried at 55°C for 8h to obtain 197.5g of an off-white solid (glapiron hydrochloride), with a yield of 91.9%.
[0065] Comparative Example 1
[0066] The A-crystalline grapipiron compound is obtained according to the A-crystalline grapipiron preparation method disclosed in patent CN113087705A.
[0067] Example 2
[0068] The glapilon hydrochloride and glapilon prepared in Example 1 and Comparative Example 1 were subjected to X-ray powder diffraction crystal form determination (XRPD), and the results are shown in Figure 1 (XRPD pattern of glapiron hydrochloride) and Figure 2 (XRPD pattern of Form A glapiron).
[0069] The detection spectrum shows that glapiron hydrochloride has no characteristic diffraction peak, and glapiron of crystal form A has characteristic diffraction peak, which proves that the glapiron hydrochloride provided by the present invention is an amorphous crystal.
[0070] Example 3
[0071] The stability of the glapilon hydrochloride prepared in Example 1 was investigated by using the A-type glapilon prepared in Comparative Example 1 as a control. The test results are shown in Table 1.
[0072] Table 1 Stability test results of glapiron hydrochloride prepared in Example 1 of the present invention
[0073] The experimental results show that the physicochemical properties of glapiron hydrochloride prepared in Example 1 are stable, and there is no obvious change in single impurities and total impurities in the influencing factor test and the accelerated test, no obvious hygroscopicity, and no change in the crystal form.
[0074] Example 4
[0075] The water solubility of the glapiron hydrochloride of the present invention was investigated, and the solubility of glapiron hydrochloride in a pH 1.2 to pH 6.8 medium and purified water was measured, with glapiron as a control. The test results are shown in Table 2:
[0076] Table 2 Solubility test results
[0077] The experimental results show that the solubility of grapipiron hydrochloride prepared in Example 1 in the four media is generally higher than that of grapipiron in crystal form A, indicating that the solubility of grapipiron hydrochloride is better than that of grapipiron in crystal form A.
[0078] Example 5
[0079] According to the prescription (weight percentage):
[0080] Preparation of glapiron hydrochloride tablets, the preparation process is as follows:
[0081] (1) glapiron hydrochloride, lactose (direct compression lactose), cross-linked polyvinylpyrrolidone and chicken liver powder are sieved through a 40-mesh sieve respectively, and then put into a mixer and mixed evenly;
[0082] (2) adding magnesium stearate into a mixer and mixing for 5 minutes until uniform to obtain a powder intermediate;
[0083] (3) The intermediate obtained in step (2) is pressed into tablets of 20 mg (calculated as glapilon), and then divided and packaged to obtain glapilon hydrochloride tablets.
[0084] Comparative Example 2
[0085] The prescription is: Grapilon 8.0% Microcrystalline Cellulose 36.0% lactose Add to 100% Copolyvidone 5.0% Sodium starch glycolate 5.0% Sodium Lauryl Sulfate 1.0% Colloidal Silica 0.5% Chicken Liver Powder 15.0% Magnesium Stearate 1.5%
[0086] Preparation of grapipiron tablets, the preparation process is as follows:
[0087] (1) micronizing grapipiron to ensure that the particle size D90 is ≤50 μm;
[0088] (2) putting micronized glapilan, microcrystalline cellulose, chicken liver powder, lactose and colloidal silicon dioxide into a mixer, mixing them evenly, then passing them through a 40-mesh sieve, and then mixing them evenly with sodium carboxymethyl starch, sodium lauryl sulfate and copovidone;
[0089] (3) adding magnesium stearate into a mixer and mixing for 5 minutes until uniform to obtain a powder intermediate;
[0090] (4) The intermediate obtained in step (3) is pressed into tablets with a specification of 20 mg / tablet, and then divided and packaged to obtain grapipiron tablets.
[0091] Comparative Example 3
[0092] The glapiron tablets (specification 20 mg, batch number 401357) produced by Eland Animal Health, Inc. of the United States were used as the sample for comparative example 3.
[0093] Example 6
[0094] The dissolution test was performed on the glapiron hydrochloride tablets and glapiron tablets prepared in Example 5 and Comparative Example 2, and the experimental conditions were:
[0095] The test results are shown in Table 3 and the dissolution curve is shown in Figures 4 to 7 ;
[0096] Table 3 Dissolution test results (unit %)
[0097] From the results in Table 3, it can be seen that the dissolution rate of the grapipiron hydrochloride tablets prepared in Example 5 is not lower than that of Comparative Example 2. In addition, the amount of cross-linked polyvinylpyrrolidone used in Example 5 is less than that of sodium carboxymethyl starch in Comparative Document 2, and the general disintegration and dissolution effect of sodium carboxymethyl starch is achieved. In addition, the grapipiron hydrochloride tablets prepared in Example 5 and the grapipiron tablets in Comparative Example 2 can both reach a dissolution rate of more than 85% within 15 minutes in a pH 1.2 to pH 6.8 and purified water medium, and the dissolution curves of the two are similar.
[0098] Example 7
[0099] The bioavailability of the glapiron hydrochloride tablets and glapiron tablets provided in Example 5 and Comparative Example 3 was measured in dogs.
[0100] The experiment adopted a double-cycle double crossover test design, and 12 dogs were randomly divided into two test groups, Group A and Group B, with 6 dogs in each group, all of which were male. In the first cycle, Group A was given the sample of Comparative Example 3, and Group B was given the sample of Example 5. After a 7-day washout period, the two groups of animals exchanged the dosing preparations, Group A was given the sample of Example 5, and Group B was given the sample of Comparative Example 3. The dosing method was based on the instructions of the grapirone tablets, with a dosage of 2 mg / kg / day, a single oral administration. Example 5 was used as the test preparation, and the sample of Comparative Example 3 was used as the reference preparation.
[0100] The sampling time was set as 0 h before administration and 0.167 / 0.333 / 0.5 / 0.75 / 1 / 1.5 / 2 / 4 / 6 / 8 / 10 / 16 / 36 h after administration. The samples were processed and then subjected to UPLC-MS / MS determination. The results were as follows: Figure 3 .
[0101] The experimental results show that the bioavailability of the grapipiron hydrochloride tablets (test preparation) prepared in Example 5 is not lower than the bioavailability of the grapipiron tablets in Comparative Example 3, and the relative bioavailability of grapipiron hydrochloride to grapipiron is 110%.
[0102] Example 8
[0103] According to the prescription (weight percentage): Glapiron hydrochloride 5.0% Crospovidone 3.0% lactose Add to 100% Chicken Liver Powder 15% Magnesium Stearate 1.0%
[0104] The glapiron hydrochloride tablets were prepared by referring to the preparation process of Example 5. The average tablet weight of the obtained tablets was 410 mg / tablet.
[0105] Example 9
[0106] According to the prescription (weight percentage): Glapiron hydrochloride 7.0% Crospovidone 3.0% lactose Add to 100% Chicken Liver Powder 15% Magnesium Stearate 1.0%
[0107] The glapiron hydrochloride tablets were prepared by referring to the preparation process of Example 5. The average tablet weight of the obtained tablets was 290 mg / tablet.
[0108] Example 10
[0109] According to the prescription (weight percentage): Glapiron hydrochloride 10.0% Crospovidone 3.0% lactose Add to 100% Chicken Liver Powder 15% Magnesium Stearate 1.0%
[0110] The glapiron hydrochloride tablets were prepared by referring to the preparation process of Example 5. The average tablet weight of the obtained tablets was 205 mg / tablet.
[0111] Embodiment 11
[0112] The dissolution curves of the glapiron hydrochloride tablets prepared in Examples 5, 8, 9 and 10 and the glapiron tablets prepared in Comparative Example 2 were compared, and a medium with discriminating power (purified water) was selected for the dissolution experiment. The specific experimental conditions are as follows: Instrument Name Dissolution Tester Dissolution medium Purified water Dissolution medium volume 900ml temperature 37℃ Speed 50rpm (paddle method)
[0113] The experimental results are shown in Table 4.
[0114] Table 4 Dissolution test results (unit %) time Example 5 Example 8 Example 9 Example 10 Comparative Example 2 5min 51.39 27.37 37.65 55.69 37.79 10min 85.51 55.38 68.15 88.69 76.09 15min 93.79 85.26 89.35 95.87 86.58 20min 96.91 90.21 95.46 97.24 89.84
[0115] The experimental results show that the dissolution rates of the glapiron hydrochloride tablets prepared in Examples 5, 8, 9 and 10 in 0-15 min are quite different, and this difference is related to the tablet weight, that is, the heavier the tablet weight, the slower the disintegration, resulting in lower solubility, but at the 15 min time point, they can all reach more than 85%. That is, the dissolution curves of the glapiron hydrochloride tablets prepared in Examples 5, 8, 9 and 10 and the glapiron tablets prepared in Comparative Example 2 in purified water medium are similar.
[0116] Note that the above are only preferred embodiments of the present invention and the technical principles used. Those skilled in the art will understand that the present invention is not limited to the specific embodiments described herein, and that various obvious changes, readjustments and substitutions can be made by those skilled in the art without departing from the scope of protection of the present invention. Therefore, although the present invention has been described in more detail through the above embodiments, the present invention is not limited to the above embodiments, and may also include more other equivalent embodiments without departing from the technical concept of the present invention, all of which belong to the protection scope of the present invention.
Claims
1. A method for preparing amorphous glapiron hydrochloride, characterized in that: The preparation method comprises: (1) 2-(4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl)ethylamine reacts with p-toluenesulfonyl isocyanate in an organic solvent, and after the reaction, water is added to the resulting solution for separation, and then the organic phase is dried to remove water, filtered, and the solvent is evaporated under reduced pressure to obtain a crude glapiolan gel product; (2) dissolving the crude colloidal product of grapipiron with hydrochloric acid, precipitating a solid at low temperature, and drying to obtain grapipiron hydrochloride; The reaction equation is as follows:
2. The preparation method according to claim 1, characterized in that: In step (1): a solution of p-toluenesulfonyl isocyanate dissolved in an organic solvent is added dropwise to a solution of 2-(4-(2-ethyl-4,6-dimethyl-1H-imidazole[4,5-c]pyridin-1-yl)phenyl)ethylamine, an organic solvent and triethylamine to carry out a reaction; Preferably, the organic solvent in step (1) is dichloromethane or ethyl acetate.
3. The preparation method according to claim 1 or 2, characterized in that: The concentration of hydrochloric acid in step (2) is 0.8 to 1.3 mol / L; Preferably, the low temperature in step (2) is 2 to 8°C; Preferably, the drying temperature in step (2) is 50-60° C., and the drying time is 6-10 h.
4. Glapiron hydrochloride prepared by the preparation method according to any one of claims 1 to 3.
5. Use of glapiron hydrochloride according to claim 4 in a pharmaceutical preparation; preferably, the pharmaceutical preparation is a tablet.
6. A pharmaceutical preparation of glapiron hydrochloride, characterized in that: The invention comprises 1.0% to 10.0% of a disintegrant, 10.0% to 20.0% of an appetite attractant, 0.5% to 1.5% of a lubricant and 5.0% to 10.0% of the glapilum hydrochloride of claim 4, and the balance is a filler.
7. The pharmaceutical preparation according to claim 6, characterized in that The composition comprises 3.0% disintegrant, 15.0% appetite attractant, 1.0% lubricant, 10.0% glapiron hydrochloride and 71.0% filler.
8. The pharmaceutical preparation according to claim 6, characterized in that It includes 3.0% disintegrant, 15.0% appetite attractant, 1.0% lubricant, 8.6% glapiron hydrochloride and 72.4% filler.
9. The pharmaceutical preparation according to any one of claims 6 to 8, characterized in that The disintegrant is at least one selected from sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, starch, and low-substituted hydroxypropyl cellulose, preferably cross-linked polyvinylpyrrolidone; Preferably, the filler is selected from at least one of pregelatinized starch, microcrystalline cellulose, lactose or mannitol, preferably lactose, and the lactose is directly compressed lactose; Preferably, the attractant is selected from one of pig liver powder, fish meal, chicken liver powder, milk powder, beef powder, meat and bone meal or yeast extract, preferably chicken liver powder; Preferably, the lubricant is selected from one of magnesium stearate, PEG3350, PEG4000, PEG6000, sodium benzoate, and sodium stearyl fumarate, preferably magnesium stearate.
10. The method for preparing the pharmaceutical preparation according to any one of claims 6 to 9, characterized in that: The sieved glapiron hydrochloride is premixed with a disintegrant, a filler and an attractant according to a proportion, and then a lubricant is added and mixed until uniform, and finally tabletted to obtain a pharmaceutical preparation.
